Therapeutics Supplements and Botanicals
RRM Academy Synopsis
Alpha-lipoic acid coincided with hematoma resolution in 3 ART cases
Among three women in a case series, all with ART pregnancies and a lasting early blood pocket beside the placenta (subchorionic hematoma), bleeding stopped within four to seven days of adding alpha-lipoic acid. The hematoma cleared on ultrasound within two to four weeks in all three.
Key Findings
- Three first-time-pregnant women with ART-conceived pregnancies and a persistent first-trimester subchorionic hematoma took oral alpha-lipoic acid alongside continued progesterone and tranexamic acid.
- The hematoma had persisted for 10 to 14 days on progesterone and tranexamic acid before alpha-lipoic acid was added.
- Vaginal bleeding stopped within four to seven days of starting alpha-lipoic acid in all three women (mean 5.3 days).
- Complete sonographic resolution came within two to four weeks in every case (mean 3 weeks).
- No maternal or fetal adverse effects were reported, and no bleeding or hematoma recurred through the end of the first trimester (12-13 weeks).
Interpretation
The report is a descriptive case series of three women with no comparison group. Each woman kept taking progesterone and tranexamic acid, and the authors list that as a limitation. The authors write that the findings are hypothesis-generating and are not evidence of efficacy until controlled trials report. The women reached pregnancy by different routes, and follow-up ended with the first trimester. Larger prospective studies would show whether the hematomas resolve without alpha-lipoic acid.
RRM Context
The authors state that ART pregnancies show more subchorionic hematoma than spontaneous conceptions. They add that lasting hematomas are linked to early loss, placental abruption and preterm birth. IVF bypasses the underlying cause of infertility. Restorative reproductive medicine treats that cause, so couples can conceive without the procedure and its added obstetric risks.
Abstract
Subchorionic hematoma (SCH) is a frequent cause of first-trimester bleeding, particularly in pregnancies conceived through assisted reproductive technologies (ART), and is associated with adverse pregnancy outcomes when persistent. Management is largely conservative, with limited targeted therapeutic options. This descriptive case series evaluated the effectiveness and safety of oral alpha-lipoic acid (ALA) as an adjunct therapy in three primigravida women with ART-conceived pregnancies complicated by persistent first-trimester SCH unresponsive to conventional management, including progesterone support and hemostatic agents. ALA was administered orally at a dose of 600 mg once daily, alongside continued standard therapy. Clinical symptoms and hematoma progression were monitored through serial transvaginal ultrasonography. All three patients experienced cessation of vaginal bleeding within four to seven days of initiating ALA therapy. Complete sonographic resolution of the hematoma was observed within two to four weeks in all cases. No maternal or fetal adverse effects were reported, and all pregnancies progressed uneventfully into the second trimester. These findings suggest that oral ALA may represent a safe and potentially effective adjunctive therapy for persistent first-trimester SCH in ART pregnancies, warranting further evaluation in larger prospective studies.
Read the guide
-
Miscarriage and Recurrent Pregnancy Loss: The Workup Most Women Never Get
Miscarriage affects approximately 15% of clinically confirmed pregnancies. Recurrent pregnancy loss (RPL), defined as two or more clinical losses, affects 2 to 5% of couples. Most causes are diagnosable and treatable. This guide covers what the standard workup misses, what RRM-trained clinicians evaluate, and what outcomes look like after cause-based treatment.


